H1N1 Influenza (Swine Flu)
- Author: Michael Stuart Bronze, MD; Chief Editor: Russell W Steele, MD more...
Swine flu is a highly contagious respiratory disease in pigs caused by one of several swine influenza A viruses (see the image below). Transmission of swine influenza viruses to humans is uncommon. However, the swine influenza virus can be transmitted to humans via contact with infected pigs or environments contaminated with swine influenza viruses.
Signs and symptoms
Manifestations of H1N1 influenza are similar to those of seasonal influenza. Patients present with symptoms of acute respiratory illness, including at least 2 of the following:
Chills and fatigue
Diarrhea and vomiting (possible)
In children, signs of severe disease include apnea, tachypnea, dyspnea, cyanosis, dehydration, altered mental status, and extreme irritability.
See Clinical Presentation for more detail.
The CDC criteria for suspected H1N1 influenza are as follows :
Onset of acute febrile respiratory illness within 7 days of close contact with a person who has a confirmed case of H1N1 influenza A virus infection, or
Onset of acute febrile respiratory illness within 7 days of travel to a community (within the United States or internationally) where one or more H1N1 influenza A cases have been confirmed, or
Acute febrile respiratory illness in a person who resides in a community where at least one H1N1 influenza case has been confirmed.
See Workup for more detail.
Treatment is largely supportive and consists of bedrest, increased fluid consumption, cough suppressants, and antipyretics and analgesics (eg, acetaminophen, nonsteroidal anti-inflammatory drugs) for fever and myalgias. Severe cases may require intravenous hydration and other supportive measures. Antiviral agents may also be considered for treatment or prophylaxis.
See Treatment and Medication for more detail.
Swine influenza is a highly contagious respiratory disease in pigs caused by one of several swine influenza A viruses. In addition, influenza C viruses may also cause illness in swine. Current strategies to control swine influenza virus (SIV) in animals typically include one of several commercially available bivalent swine influenza virus vaccines.
Transmission of swine influenza viruses to humans is uncommon. However, the swine influenza virus can be transmitted to humans via contact with infected pigs or environments contaminated with swine influenza viruses. Once a human becomes infected, he or she can then spread the virus to other humans, presumably in the same way as seasonal influenza is spread (ie, via coughing or sneezing).
The ability to trace outbreaks of swine flu in humans dates back to investigation of the 1918 Spanish influenza pandemic, which infected one third of the world’s population (an estimated 500 million people) and caused approximately 50 million deaths. In 1918, the cause of human influenza and its links to avian and swine influenza was not understood. The answers did not begin to emerge until the 1930s, when related influenza viruses (now known as H1N1 viruses) were isolated from pigs and then humans.
In humans, the severity of swine influenza can vary from mild to severe. From 2005 until January 2009, 12 human cases of swine flu were reported in the United States. None were fatal. In 1988, however, a previously healthy 32-year-old pregnant woman in Wisconsin died of pneumonia as a complication of swine influenza.
A 1976 outbreak of swine influenza in Fort Dix, New Jersey, involved more than 200 cases, some of them severe, and one death. The first discovered case involved a soldier at Fort Dix who complained of feeling weak and tired. He died the next day.
The fear of an influenza pandemic in 1976 led to a national campaign in the United States designed to immunize nearly the entire population. In October, 1976, approximately 40 million people received the A/NewJersey/1976/H1N1 vaccine (ie, swine flu vaccine) before the immunization initiative was halted because of the strong association between the vaccine and Guillain-Barré syndrome (GBS).[5, 6] About 500 cases of GBS were reported, with 25 deaths due to associated pulmonary complications.
A recent investigation sought to determine the link between GBS and the 1976 swine flu vaccine, since subsequent influenza vaccines did not have this strong association. Nachamkin et al found that inoculation of the 1976 swine flu vaccine, as well as the 1991-1992 and 2004-2005 influenza vaccines, into mice prompted production of antibodies to antiganglioside (anti-GM1), which are associated with the development of GBS. They proposed that further research regarding influenza vaccine components is warranted to determine how these components elicit antiganglioside effects. See the images below.
Current H1N1 influenza (formerly called swine influenza) outbreak
Human cases of influenza A (H1N1) have been reported worldwide. In 2009, cases of influenzalike illness were first reported in Mexico on March 18; the outbreak was subsequently confirmed as H1N1 influenza A. Investigation is continuing to clarify the spread and severity of H1N1 influenza (swine flu) in Mexico. Suspected clinical cases had been reported in 19 of the country's 32 states. Although only 97 of the Mexican cases had been laboratory-confirmed as Influenza A/H1N1 (12 of them genetically identical to Influenza A/H1N1 viruses from California ). As of May 5th, 2009, nearly 600 H1N1 influenza cases had been confirmed in Mexico, including 25 deaths.
On April 17, 2009, the CDC determined that two cases of febrile respiratory illness in children who resided in adjacent counties in southern California were caused by infection with a swine influenza A (H1N1) virus. By April 26, 2009, the US Department of Health and Human Services declared a national public health emergency involving H1N1 influenza A, citing its significant potential to affect national security. By June 25, 2009, 27,717 lab-defined cases of H1N1 influenza had been confirmed in the United States.[10, 14, 15, 16]
Estimates in the United States for the first 6 months of the pandemic report approximately 22 million people in the United States became ill from the H1N1 influenza, nearly 100,000 were hospitalized, and about 3900 have died. Deaths include an estimated 540 children younger than 18 years, 2900 adults aged 18-64 years, and about 440 elderly individuals. These estimates are from the CDC's Emerging Infection Program, rather than using only laboratory-confirmed cases.
For an updated tally and case counts in specific states, see the CDC's H1N1 Flu (Swine Flu) Web page.
On June 11, 2009, WHO raised the pandemic alert level to phase 6 (indicating a global pandemic) because of widespread infection beyond North America to Australia, the United Kingdom, Argentina, Chile, Spain, and Japan. As of September 1, 2009, the World Health Organization (WHO) reported that H1N1 influenza had been confirmed in over 200,000 people in more than 100 countries and that they are aware of at least 2185 confirmed deaths. For an updated tally of affected countries and counts, see WHO's Influenza A (H1N1) Web page.
On October 24, 2009, President Obama declared the 2009 H1N1 influenza pandemic a national emergency, explaining that "...the rapid increase in illness across the Nation may overburden health care resources and that the temporary waiver of certain standard Federal requirements may be warranted in order to enable U.S. health care facilities to implement emergency operations plans, the in the United States 2009 H1N1 influenza pandemic constitutes a national emergency." This declaration makes way for waiving certain requirements of the Medicare, Medicaid, and State Children's Health Insurance programs and of the Health Insurance Portability and Accountability Act Privacy Rule throughout the duration of the public health emergency.
Government and public health officials are monitoring this situation worldwide to assess the threat from H1N1 influenza and to provide guidance to health care professionals and the public. Because the situation is changing rapidly, it is important to check regularly for changes in recommendations as new information becomes available. Online resources for daily guidance include the Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), and Medscape's H1N1 Influenza A (Swine Flu) Alert Center.
Domínguez-Cherit et al (2009) conducted an observational study of consecutive critically ill patients in Mexican hospitals that treated most patients with confirmed, probable, or suspected H1N1 influenza during the 2009 epidemic. Critical illness occurred in 58 (6.5%) of 899 patients. Median age of critically ill patients was 44 years (range, 10-83 y). All presented with fever, and all but one with respiratory symptoms. Few patients had comorbid respiratory disorders, but 36% were obese. All patients but 2 received mechanical ventilation for severe acute respiratory distress syndrome and refractory hypoxemia. By 60 days, 24 patients had died (41.4%; 95% confidence interval, 28.9%-55%). Patients who died had greater initial severity of illness, worse hypoxemia, higher creatine kinase and creatinine levels, and ongoing organ dysfunction. Treatment with neuraminidase inhibitors was associated with improved survival (odds ratio, 8.5; 95% confidence interval, 1.2-2.8).
See Medscape's H1N1 influenza algorithm adaptation for guidance in managing suspected cases.
A WHO report on the 2009 influenza pandemic indicated that nearly all countries reported cases of H1N1 virus infection, with more than 17,000 deaths worldwide. In the United States, the number of clinical illnesses was estimated at 59 million, 265,000 hospitalizations, and 12,000 deaths. . H1N1 strains are still prevalent in India, whose Health Ministry has reported over 2500 deaths to date.
In the second half of 2011, a novel swine influenza virus emerged. Twelve cases from 5 states were reported by the CDC in January 2012. The new strain, dubbed A (H3N2)v, includes a gene from the human pandemic strain and affects mostly children. In 3 of the 5 states where the virus emerged (Pennsylvania, Maine, and Indiana), the virus was a result of pig-to-human transmission. According to the Department of Health and Human Services (HHS), a precautionary vaccine against this variant is in development and will likely be ready for clinical trials in the spring of 2012.
H1N1 influenza (swine flu) tends to cause high morbidity but low mortality rates (1%-4%).
Belongia et al provide an excellent epidemiologic comparison of the clinical characteristics of the 2009 influenza A H1N1 versus other seasonal influenza A strains. In their study, the clinical manifestations and risk for hospitalization were similar between the 2009 H1N1 strain and other seasonal influenza A strains. However, children were disproportionately affected by the 2009 H1N1 strain but not necessarily by severity of illness.
CDC. Interim Guidance for Clinicians on the Prevention and Treatment of Swine-Origin Influenza Virus Infection in Young Children. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/childrentreatment.htm. Accessed: April 30, 2009.
CDC. Interim Guidance on Specimen Collection and Processing for Patients with Suspected Swine Influenza A (H1N1) Virus Infection. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/specimencollection.htm. Accessed: April 28, 2009.
Taubenberger JK, Morens DM. 1918 Influenza: the mother of all pandemics. Emerg Infect Dis. 2006 Jan. 12(1):15-22. [Medline].
Bresee J. CDC Podcasts: Swine Flu. Centers for Disease Control and Prevention. Available at http://www2c.cdc.gov/podcasts/player.asp?f=11226. Accessed: April 28, 2009.
Roan S. Swine flu 'debacle' of 1976 is recalled. LA Times. April 27, 2009. Available at http://articles.latimes.com/2009/apr/27/science/sci-swine-history27.
CDC. Swine Flu - Vaccine Safety and Emergency Preparedness. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/vaccinesafety/emergency/swineflu.htm. Accessed: April 29, 2009.
Vellozzi C, Burwen DR, Dobardzic A, Ball R, Walton K, Haber P. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine. 2009 Mar 26. 27(15):2114-20. [Medline].
Nachamkin I, Shadomy SV, Moran AP, Cox N, Fitzgerald C, Ung H, et al. Anti-ganglioside antibody induction by swine (A/NJ/1976/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barré syndrome. J Infect Dis. 2008 Jul 15. 198(2):226-33. [Medline].
World Health Organization. Influenza-like illness in the United States and Mexico. WHO Epidemic and Pandemic Alert and Response. Available at http://www.who.int/csr/don/2009_04_24/en/index.html. Accessed: April 27, 2009.
WHO. Influenza A (H1N1): Special Insights. World Health Organization. Available at http://www.who.int/en/. Accessed: September 1, 2009.
McNeil DG Jr. U.S. Declares Public Health Emergency Over Swine Flu. New York Times. April 27, 2009. Available at http://www.nytimes.com/2009/04/27/world/27flu.html?th&emc=th.
U.S. Department of Health and Human Services. Determination That a Public Health Emergency Exists. Available at http://www.hhs.gov/secretary/phe_swh1n1.html. Accessed: April 27, 2009.
CDC. Swine Influenza (Flu). Centers for Disease Control and Prevention. Available at http://www.cdc.gov/h1n1flu/. Accessed: September 1, 2009.
Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med. 2009 Jun 18. 360(25):2605-15. [Medline].
Centers for Disease Control and Prevention (CDC). Update: novel influenza A (H1N1) virus infections - worldwide, May 6, 2009. MMWR Morb Mortal Wkly Rep. 2009 May 8. 58(17):453-8. [Medline].
CDC. CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April - October 17, 2009. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm.
Obama Declares Swine Flu A National Emergency. The New York Times. October 24, 2009. Available at http://www.nytimes.com/reuters/2009/10/24/world/international-uk-flu-usa-obama.html.
Domínguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, de la Torre A, et al. Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA. 2009 Nov 4. 302(17):1880-7. [Medline].
Bautista E, Chotpitayasunondh T, Gao Z, Harper SA, Shaw M, Uyeki TM, et al. Clinical aspects of pandemic 2009 influenza A (H1N1) virus infection. N Engl J Med. 2010 May 6. 362(18):1708-19. [Medline]. [Full Text].
Update: Influenza A (H3N2)v Transmission and Guidelines - Five States, 2011. MMWR Morb Mortal Wkly Rep. 2012 Jan 6. 60:1741-4. [Medline].
Belongia EA, Irving SA, Waring SC, et al. Clinical characteristics and 30-day outcomes for influenza A 2009 (H1N1), 2008-2009 (H1N1), and 2007-2008 (H3N2) infections. JAMA. 2010 Sep 8. 304(10):1091-8. [Medline].
Khandaker G, Zurynski Y, Buttery J, Marshall H, Richmond PC, Dale RC, et al. Neurologic complications of influenza A(H1N1)pdm09: Surveillance in 6 pediatric hospitals. Neurology. 2012 Oct 2. 79(14):1474-1481. [Medline].
CDC. Guidance for Clinicians & Public Health Professionals. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/guidance/. Accessed: April 27, 2009.
National Center for Biotechnology Information. Influenza Virus Resource. Available at http://www.ncbi.nlm.nih.gov/genomes/FLU/SwineFlu.html. Accessed: May 4, 2009.
NIAID. NIAID and 2009 H1N1 influenza. National Institute of Allergy and Infectious Diseases. Available at http://www.niaid.nih.gov/topics/flu/h1n1/research/Pages/researchProgram.aspx. Accessed: May 4, 2009.
WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. World Health Organization. Available at http://www.who.int/csr/resources/publications/swineflu/h1n1_use_antivirals_20090820/en/index.html. Accessed: August 20, 2009.
Graitcer SB, Gubareva L, Kamimoto L, et al. Characteristics of Patients with Oseltamivir-Resistant Pandemic (H1N1) 2009, United States. Emerg Infect Dis. 2011 Feb. 17(2):255-257. [Medline].
Hernandez JE, Adiga R, Armstrong R, et al. Clinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an Emergency IND program in the United States. Clin Infect Dis. 2011 Mar. 52(6):695-706. [Medline]. [Full Text].
CDC. Interim Guidance on Antiviral Recommendations for Patients with Confirmed or Suspected Swine Influenza A (H1N1) Virus Infection and Close Contacts. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/recommendations.htm. Accessed: April 28, 2009.
Oseltamivir-resistant 2009 pandemic influenza A (H1N1) virus infection in two summer campers receiving prophylaxis--North Carolina, 2009. MMWR Morb Mortal Wkly Rep. 2009 Sep 11. 58(35):969-72. [Medline].
Lee VJ, Yap J, Cook AR, Chen MI, Tay JK, Tan BH, et al. Oseltamivir ring prophylaxis for containment of 2009 H1N1 influenza outbreaks. N Engl J Med. 2010 Jun 10. 362(23):2166-74. [Medline].
Maternal and Infant Outcomes Among Severely Ill Pregnant and Postpartum Women with 2009 Pandemic Influenza A (H1N1) --- United States, April 2009--August 2010. MMWR Morb Mortal Wkly Rep. 2011 Sep 9. 60:1193-6. [Medline]. [Full Text].
CDC. Interim Guidance - Pregnant women and swine influenza: considerations for clinicians. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/clinician_pregnant.htm. Accessed: April 29, 2009.
Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R. Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. Influenza Other Respi Viruses. 2011 Mar 21. [Medline].
US Food and Drug Administration. Influenza Virus Vaccine for the 2013-2014 Season. Available at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/ucm343828.htm. Accessed: March 15, 2013.
Jackson LA, Chen WH, Stapleton JT, Dekker CL, Wald A, Brady RC, et al. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons. J Infect Dis. 2012 Sep 15. 206(6):811-20. [Medline]. [Full Text].
CDC 2009 H1N1 vaccination campaign planning checklist. August 31, 2009. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/H1N1flu/vaccination/statelocal/planning_checklist.htm. Accessed: September 1, 2009.
CDC. Novel H1N1 vaccination recommendations. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/h1n1flu/vaccination/acip.htm. Accessed: September 1, 2009.
Pasternak B, Svanström H, Mølgaard-Nielsen D, Krause TG, Emborg HD, Melbye M, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ. 2012 May 2. 344:e2794. [Medline]. [Full Text].
CDC. Interim Guidance for Infection Control for Care of Patients with Confirmed or Suspected Swine Influenza A (H1N1) Virus Infection in a Healthcare Setting. Centers for Disease Control and Prevention. Available at http://www.cdc.gov/swineflu/guidelines_infection_control.htm. Accessed: April 29, 2009.
Zhu FC, Wang H, Fang HH, Yang JG, Lin XJ, Liang XF, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med. 2009 Dec 17. 361(25):2414-23. [Medline].
US Food and Drug Administration. Letter from the Commissioner to Nation’s Health Care Professionals on H1N1 Vaccine Safety. Available at http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm197733.htm. Accessed: January 14, 2010.
Jain S, Benoit SR, Skarbinski J, Bramley AM, Finelli L. Influenza-Associated Pneumonia Among Hospitalized Patients With 2009 Pandemic Influenza A (H1N1) Virus--United States, 2009. Clin Infect Dis. 2012 May. 54(9):1221-1229. [Medline].
Myles PR, Semple MG, Lim WS, Openshaw PJ, Gadd EM, Read RC, et al. Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009-2010 in the UK. Thorax. 2012 Mar 14. [Medline].
Jamieson DJ, Honein MA, Rasmussen SA, Williams JL, Swerdlow DL, Biggerstaff MS, et al. H1N1 2009 influenza virus infection during pregnancy in the USA. Lancet. 2009 Aug 8. 374(9688):451-8. [Medline].
Siston AM, Rasmussen SA, Honein MA, Fry AM, Seib K, Callaghan WM, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA. 2010 Apr 21. 303(15):1517-25. [Medline].
Pierce M, Kurinczuk JJ, Spark P, Brocklehurst P, Knight M. Perinatal outcomes after maternal 2009/H1N1 infection: national cohort study. BMJ. 2011 Jun 14. 342:d3214. [Medline].
CDC. Swine Flu: CDC Offers Clinical Guidance, WHO Raises Alert Level Again. Physician First Watch - Journal Watch. Available at http://firstwatch.jwatch.org/cgi/content/full/2009/430/1. Accessed: April 30, 2009.
Kling J. Triple-Dose Flu Remedy Hastens H1N1 Viral Clearance. Medscape [serial online]. Available at http://www.medscape.com/viewarticle/811132. Accessed: September 24, 2013.
Kumar A, ROSII Study Investigators. Viral Clearance with Standard or Triple Dose Oseltamivir Therapy in Critically Ill Patients with Pandemic (H1N1) 2009 Influenza. Abstract V-1470. Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Available at http://www.icaaconline.com/php/icaac2013abstracts/data/papers/2013/V/2013_V-1470.htm. Accessed: September 24, 2013.
WHO. Swine Influenza Frequently Asked Questions. World Health Organization. Available at http://www.who.int/csr/swine_flu/swine_flu_faq_26april.pdf. Accessed: April 27, 2009.